{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:59:21Z","timestamp":1790665161322,"version":"4.1.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,4,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interferon (IFN) is effective at inducing complete remissions in patients with chronic myelogenous leukemia (CML), and evidence supports an immune mechanism. Here we show that the type I IFNs (alpha and beta) regulate expression of the IFN consensus sequence-binding protein (ICSBP) in BCR-ABL\u2013transformed cells and as shown previously for ICSBP, induce a vaccine-like immunoprotective effect in a murine model of BCR-ABL\u2013induced leukemia. We identify the chemokines CCL6 and CCL9 as genes prominently induced by the type I IFNs and ICSBP, and demonstrate that these immunomodulators are required for the immunoprotective effect of ICSBP expression. Insights into the role of these chemokines in the antileukemic response of IFNs suggest new strategies for immunotherapy of CML.<\/jats:p>","DOI":"10.1182\/blood-2008-07-167189","type":"journal-article","created":{"date-parts":[[2009,1,27]],"date-time":"2009-01-27T01:45:35Z","timestamp":1233020735000},"page":"3813-3820","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["ICSBP-mediated immune protection against BCR-ABL\u2013induced leukemia requires the CCL6 and CCL9 chemokines"],"prefix":"10.1182","volume":"113","author":[{"given":"Valentina","family":"Nardi","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Children's Hospital Boston and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaia","family":"Naveiras","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Children's Hospital Boston and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Azam","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Children's Hospital Boston and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Q.","family":"Daley","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Children's Hospital Boston and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111713273083100_B1","doi-asserted-by":"crossref","first-page":"5826","DOI":"10.1038\/sj.onc.1204549","article-title":"Cooperative and redundant effects of STAT5 and Ras signaling in BCR\/ABL transformed hematopoietic cells.","volume":"20","author":"Hoover","year":"2001","journal-title":"Oncogene"},{"key":"2019111713273083100_B2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","article-title":"Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells.","volume":"86","author":"Skorski","year":"1995","journal-title":"Blood"},{"key":"2019111713273083100_B3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF02981952","article-title":"Mechanisms of transformation by the BCR\/ABL oncogene.","volume":"73","author":"Sattler","year":"2001","journal-title":"Int J Hematol"},{"key":"2019111713273083100_B4","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1038\/sj.onc.1206090","article-title":"The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.","volume":"21","author":"Ren","year":"2002","journal-title":"Oncogene"},{"key":"2019111713273083100_B5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.12.7.968","article-title":"A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.","volume":"12","author":"Reuther","year":"1998","journal-title":"Genes Dev"},{"key":"2019111713273083100_B6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"2019111713273083100_B7","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"2019111713273083100_B8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2002.20.1.214","article-title":"Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa.","volume":"20","author":"Mahon","year":"2002","journal-title":"J Clin Oncol"},{"key":"2019111713273083100_B9","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1182\/blood.V79.8.1920.1920","article-title":"Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy.","volume":"79","author":"Lee","year":"1992","journal-title":"Blood"},{"key":"2019111713273083100_B10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2141.1995.tb05257.x","article-title":"Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.","volume":"91","author":"Hochhaus","year":"1995","journal-title":"Br J Haematol"},{"key":"2019111713273083100_B11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cytogfr.2007.06.015","article-title":"The role of interferon-alpha in the treatment of chronic myeloid leukemia.","volume":"18","author":"Kujawski","year":"2007","journal-title":"Cytokine Growth Factor Rev"},{"key":"2019111713273083100_B12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","article-title":"Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.","volume":"101","author":"Burchert","year":"2003","journal-title":"Blood"},{"key":"2019111713273083100_B13","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood.V90.7.2529","article-title":"Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.","volume":"90","author":"Molldrem","year":"1997","journal-title":"Blood"},{"key":"2019111713273083100_B14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"key":"2019111713273083100_B15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0092-8674(00)81348-3","article-title":"Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.","volume":"87","author":"Holtschke","year":"1996","journal-title":"Cell"},{"key":"2019111713273083100_B16","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1128\/MCB.20.4.1149-1161.2000","article-title":"Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.","volume":"20","author":"Hao","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2019111713273083100_B17","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood.V97.11.3491","article-title":"Expression of interferon consensus sequence binding protein induces potent immunity against BCR\/ABL-induced leukemia.","volume":"97","author":"Deng","year":"2001","journal-title":"Blood"},{"key":"2019111713273083100_B18","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1182\/blood-2003-08-2970","article-title":"Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR\/ABL and down-regulates bcl-2.","volume":"103","author":"Burchert","year":"2004","journal-title":"Blood"},{"key":"2019111713273083100_B19","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood-2003-01-0291","article-title":"ICSBP\/IRF-8 inhibits mitogenic activity of p210 Bcr\/Abl in differentiating myeloid progenitor cells.","volume":"102","author":"Tamura","year":"2003","journal-title":"Blood"},{"key":"2019111713273083100_B20","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood-2003-01-0285","article-title":"The interferon regulatory factor ICSBP\/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells.","volume":"103","author":"Schmidt","year":"2004","journal-title":"Blood"},{"key":"2019111713273083100_B21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V91.1.22","article-title":"Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias.","volume":"91","author":"Schmidt","year":"1998","journal-title":"Blood"},{"key":"2019111713273083100_B22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1074-7613(00)00016-9","article-title":"ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages.","volume":"13","author":"Tamura","year":"2000","journal-title":"Immunity"},{"key":"2019111713273083100_B23","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.4049\/jimmunol.169.3.1261","article-title":"IFN consensus sequence binding protein\/IFN regulatory factor-8 guides bone marrow progenitor cells toward the macrophage lineage.","volume":"169","author":"Tsujimura","year":"2002","journal-title":"J Immunol"},{"key":"2019111713273083100_B24","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1084\/jem.20021263","article-title":"ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells.","volume":"196","author":"Schiavoni","year":"2002","journal-title":"J Exp Med"},{"key":"2019111713273083100_B25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood-2002-04-1088","article-title":"Essential role for ICSBP in the in vivo development of murine CD8alpha+ dendritic cells.","volume":"101","author":"Aliberti","year":"2003","journal-title":"Blood"},{"key":"2019111713273083100_B26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(85)80053-2","article-title":"Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo.","volume":"41","author":"Palacios","year":"1985","journal-title":"Cell"},{"key":"2019111713273083100_B27","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL.","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"key":"2019111713273083100_B28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1251\/bpo63","article-title":"A screen to identify drug resistant variants to target-directed anti-cancer agents.","volume":"5","author":"Azam","year":"2003","journal-title":"Biol Proced Online"},{"key":"2019111713273083100_B29","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1073\/pnas.87.10.3743","article-title":"An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes.","volume":"87","author":"Driggers","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111713273083100_B30","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1182\/blood.V86.10.3897.bloodjournal86103897","article-title":"The SH2 domain of P210BCR\/ABL is not required for the transformation of hematopoietic factor-dependent cells.","volume":"86","author":"Ilaria","year":"1995","journal-title":"Blood"},{"key":"2019111713273083100_B31","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood.V97.5.1404","article-title":"Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR\/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.","volume":"97","author":"Peters","year":"2001","journal-title":"Blood"},{"key":"2019111713273083100_B32","doi-asserted-by":"crossref","first-page":"10058","DOI":"10.1128\/MCB.24.22.10058-10071.2004","article-title":"FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5\/BCL6-dependent mechanism.","volume":"24","author":"Fernandez de Mattos","year":"2004","journal-title":"Mol Cell Biol"},{"key":"2019111713273083100_B33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.leu.2403998","article-title":"The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.","volume":"20","author":"Cilloni","year":"2006","journal-title":"Leukemia"},{"key":"2019111713273083100_B34","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.4049\/jimmunol.155.11.5352","article-title":"Molecular cloning and functional characterization of a novel member of the C-C chemokine family.","volume":"155","author":"Hara","year":"1995","journal-title":"J Immunol"},{"key":"2019111713273083100_B35","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.cell.2006.01.040","article-title":"A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen.","volume":"124","author":"Moffat","year":"2006","journal-title":"Cell"},{"key":"2019111713273083100_B36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng1117","article-title":"A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference.","volume":"33","author":"Rubinson","year":"2003","journal-title":"Nat Genet"},{"key":"2019111713273083100_B37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.med.50.1.369","article-title":"The graft-versus-leukemia effects of allogeneic cell therapy.","volume":"50","author":"Porter","year":"1999","journal-title":"Annu Rev Med"},{"key":"2019111713273083100_B38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/10428190210202","article-title":"Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation.","volume":"43","author":"Leis","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"2019111713273083100_B39","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"2019111713273083100_B40","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"2019111713273083100_B41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002770050246","article-title":"Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation.","volume":"74","author":"Jiang","year":"1997","journal-title":"Ann Hematol"},{"key":"2019111713273083100_B42","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1182\/blood-2004-06-2229","article-title":"Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model.","volume":"104","author":"Krause","year":"2004","journal-title":"Blood"},{"key":"2019111713273083100_B43","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.4049\/jimmunol.171.6.2797","article-title":"CCL9 is secreted by the follicle-associated epithelium and recruits dome region Peyer's patch CD11b+ dendritic cells.","volume":"171","author":"Zhao","year":"2003","journal-title":"J Immunol"},{"key":"2019111713273083100_B44","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.4049\/jimmunol.179.8.5474","article-title":"The chemokine CCL6 promotes innate immunity via immune cell activation and recruitment.","volume":"179","author":"Coelho","year":"2007","journal-title":"J Immunol"},{"key":"2019111713273083100_B45","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1038\/sj.onc.1210146","article-title":"Expression of CCL9\/MIP-1gamma is repressed by BCR\/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR\/ABL cells.","volume":"26","author":"Iotti","year":"2007","journal-title":"Oncogene"},{"key":"2019111713273083100_B46","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/10428199509059647","article-title":"Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.","volume":"18","author":"Pawelec","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"2019111713273083100_B47","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1080\/1042819031000110973","article-title":"Immunological effects of interferon-alpha on chronic myelogenous leukemia.","volume":"44","author":"de Castro","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"2019111713273083100_B48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/asheducation-2003.1.331","article-title":"Immunotherapy of hematologic malignancy.","author":"Heslop","year":"2003","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/16\/3813\/1307681\/zh801609003813.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/16\/3813\/1307681\/zh801609003813.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T19:20:36Z","timestamp":1684869636000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/113\/16\/3813\/25078\/ICSBPmediated-immune-protection-against"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,16]]},"references-count":48,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2009,4,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-07-167189","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,16]]}}}